Coiled Therapeutics Plc COIL

NEW YORK, NY / ACCESS Newswire / October 1, 2026 / today will host eight micro and small cap public companies and a select audience of institutional and other qualified investors in New York City for a full day of company presentations, one on one meetings, and networking.The investor focused conference provides meaningful access to executive management teams and differentiated small cap investment opportunities.

Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) said it expects to report the first safety data from a new version of its cancer drug AO-252 before the end of 2026. The developer of treatments for cancers driven by specific genetic changes plans to dose up to 30 patients with the new formulation...

Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) executive chairman Dr Sotirios Stergiopoulos spoke with Proactive's Stephen Gunnion about progress with the company's new drug formulation of AO-252, including the enrolment of the first six patients across the 120mg twice-daily and 160mg once-daily cohorts. Stergiopoulos explained that the initial cohorts are designed to provide important exposure data for the new formulation. The previous version had encountered solubility limitations as doses increased, restricting how much drug reached the patient, and Coiled is now looking to establish whether t

Shore Capital has welcomed the latest step forward in Coiled Therapeutics' (AIM:COIL, OTCQB:COTXF) cancer drug trial, reiterating its support for the AIM-listed group. The broker was responding to Monday's news that Coiled had enrolled six patients across two dose groups testing a...

FTSE 100 up 113 points at 10,773 Wall Street headed for a positive start Miners and banks lead blue-chip gains Oil producers fall as crude retreats 4:15pm: Nasdaq reaches all-time high Optimism returned to Wall Street on Monday, with chip stocks leading a broad technology rally and...

Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) has enrolled its first patients into two new dose groups for a reformulated cancer drug. The company's aiming to dose up to 30 patients by the end of the year. Eco Buildings Group PLC (AIM:ECOB, FRA:9ZL0) has signed a deal to build at least 10,000 homes in The Gambia. It's calling this the most significant international development in the company's history. Anglo Asian Mining Plc (LSE:AAZ, OTC:AGXKF, FRA:A4A) has retained its copper guidance after a record first half. Revenue more than tripled thanks to full production from its Gilar and Demirli mine

Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) has enrolled the first patients into two dose groups testing a reformulated version of its experimental cancer drug. The AIM-listed oncology group said it had signed up three patients each to a twice-daily 120mg cohort and a once-daily 160mg cohort...

CelLBxHealth PLC (AIM:CLBX, FRA:DWV) jumped 6% after a new study showed its Parsortix system can spot cancer drug targets in blood samples. It even caught targets that rival tests would've missed completely. Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) has dosed its first US patient with a reworked version of its cancer drug AO-252. The new capsule fixes an absorption problem and no safety issues have shown up yet. Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) got fast-tracked examination from the US patent office for its longevity gene variant. It's also had a second patent publishe

Coiled Therapeutics (AIM:COIL, OTCQB:COTXF), the AIM-quoted cancer drug developer, said the first patient in the United States has been dosed with a reworked version of its lead treatment, AO-252, with no treatment-related safety findings in initial monitoring. The switch is intended to fix...

Coiled Therapeutics (AIM:COIL) is introducing a new softgel formulation of its lead cancer drug candidate AO-252 to improve absorption and consistency. The first patient is expected to be dosed this month, with data from expansion cohorts due in the second half of the year. IXICO (LSE:IXI) has upgraded its revenue forecast to at least £8 million for the current financial year, up from earlier guidance of £7.5 million. That represents growth of around 22% on last year, driven by new contract wins and a broader client base. EnSilica (AIM:ENSI) has raised around £14 million through an oversubscri

Coiled Therapeutics (AIM:COIL, OTCQB:COTXF), a clinical-stage oncology company developing medicines for hard-to-treat cancers, has created a new oral formulation of its lead drug candidate designed to improve how the treatment is absorbed by the body. The AIM-listed company said it expects to...

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here. The presentations will be available 24/7 for 90 days. Investors, advisors, and ana

Coiled Therapeutics (AIM:COIL, OTCQB:COTXF), the AIM-listed clinical-stage oncology company, has appointed Craig Tooman as an independent non-executive director with effect from 25 June. Tooman most recently served as president, chief executive and board director of Silence Therapeutics, the...

Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) has brought its Icaco-2 well in Colombia on production at around 830 barrels per day gross, taking total corporate output to approximately 5,000 barrels of oil equivalent per day. CEO Marshall Abbott says the Icaco discovery "may be material to Arrow," with horizontal and vertical development wells already planned. Frontier IP Group PLC (LSE:FIPP, FRA:8WT) has raised £4 million through a placing and subscription at 12p per share, with six directors participating in the subscription element. A retail offer through BookBuild is also open, ai

Coiled Therapeutics (AIM:COIL, OTCQB:COTXF), the clinical-stage oncology company, has appointed two senior cancer drug developers to a newly formed medical advisory board guiding its lead programme, AO-252. Professor Guru Sonpavde and Dr Alexander Spira join as founding members as the...

Active Energy Group PLC (AIM:AEG, OTCID:AEUSF) says its Ghummud facility in Abu Dhabi generated $110,000 in revenue in its first full month, with 97% uptime. The company is now targeting expansion into Bahrain and Saudi Arabia using the same infrastructure-led model. Quantum Blockchain Technologies PLC (AIM:QBT) says integration of a new ASIC mining rig is complete and data is now flowing into its Method C AI Oracle. Management expects it has enough data for training, with live deployment still targeted by the end of June. Metir PLC (AIM:MET) has secured its first PFAS detector sale to Nasdaq-

Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) executive chairman Dr Sotirios Stergiopoulos joined Proactive's Stephen Gunnion to discuss the appointment of Professor Ozgur Sahin as a Scientific Advisor to the company and the progress of lead cancer therapy AO-252. Stergiopoulos explained why Sahin, a leading expert in TACC3 biology, is a key addition as the company advances the programme. He also highlighted encouraging early clinical data, including signs of tumour regression with no safety concerns reported to date, and outlined plans to begin dosing patients with a new AO-252 formulation in J